PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
The purpose of this study it to evaluate the efficacy of PTK787/ZK 222584, in inducing at
 least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein
 levels are < 5 g/dL following high dose chemotherapy (HDCT) and autologous stem cell
 transplantation (ASCT).
To evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in
 paraprotein in patients with multiple myeloma whose paraprotein levels are < 5 g/dL following
 high dose chemotherapy (HDCT) and Autologous Stem Cell Transplantation (ASCT).

 To assess the time to progression and disease free survival of patients treated with
 PTK787/ZK 222584.

 To assess the safety and tolerability of PTK787/ZK 222584 in multiple myeloma patients
 following ASCT.
Inclusion Criteria:

 -  Patients eligible for this trial are those diagnosed with multiple myeloma by standard
 criteria and treated with HDCT and ASCT on protocols at Washington University School
 of Medicine. Following HDCT and ASCT patients must have:

 1. M-component (IgG or IgA) with persistent measurable paraprotein, or >=2 g
 monoclonal protein in 24 hr urine specimen or patients with an abnormal serum
 kappa/lambda ratio and a level of kappa or lambda light chain > 10 mg/dl.

 2. >=90 days and <= 120 days post transplant

 3. Laboratory values less than or equal to 2 weeks prior to initiation of treatment:

 -  Absolute neutrophil count (ANC) greater than or equal 1.5 x 10^9/L

 -  Platelets (PLT) greater than or equal to 100 x 10^9/L

 -  Hemoglobin (Hgb) greater than or equal to 9 g/dL

 -  Serum creatinine less than or equal to 1.5 upper limit of normal (ULN)

 -  Serum bilirubin less than or equal to 1.5 ULN

 -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase
 (ALT/SGPT) less than or equal to 3.0 x ULN

 -  Negative for proteinuria based on dip stick reading OR, if documentation of
 +1 result for protein on dip stick reading, then total urinary albumin ≤ 500
 mg and measured creatinine clearance (CrCl) greater than or equal to 50
 mL/min from a 24-hour urine collection

 4. A negative pregnancy test 48 hours prior to study treatment and must not be
 lactating if they are females of childbearing age.

 5. Ability to understand and the willingness to sign a written informed consent
 document in accordance with the guidelines of the Washington University Human
 Studies Committee.

 6. Age greater than or equal to 18 years old.

 7. ECOG performance status less than or equal to 2.

 Exclusion Criteria:

 1. Receiving any other investigational agents.

 2. Receiving concurrent steroids with a dose equivalent of prednisone of >= 150 mg/month.

 3. Female patients who are pregnant or breast feeding, or adults of reproductive
 potential not employing an effective method of birth control. Barrier contraceptives
 must be used throughout the trial in both sexes. Oral, implantable, or injectable
 contraceptives may be affected by cytochrome P450 interactions, and are therefore not
 considered effective for this study.

 4. Biopsy proven amyloidosis.

 5. Patients with a history of another primary malignancy within less than or equal to 5
 years, with the exception of inactive basal or squamous cell carcinoma of the skin.

 6. Prior chemotherapy less than or equal to 3 weeks prior to registration and/or
 randomization. Patients must have recovered from all therapy-related toxicities.

 7. Prior biologic or immunotherapy less than or equal to 2 weeks prior to registration
 and/or randomization. Patients must have recovered from all therapy-related
 toxicities.

 8. Prior full field radiotherapy less than or equal to 4 weeks or limited field
 radiotherapy less than or equal to 2 weeks prior to randomization. Patients must have
 recovered from all therapy-related toxicities.

 9. Pleural effusion or ascites that cause respiratory compromise (greater than or equal
 to CTC grade 2 dyspnea).

 10. Major surgery (i.e. laparotomy) less than or equal to 4 weeks prior to randomization.
 Minor surgery less than or equal to 2 weeks prior to randomization. Insertion of a
 vascular access device is not considered major or minor surgery in this regard.
 Patients must have recovered from all surgery-related toxicities.

 11. Patients who have received investigational drugs less than or equal to 4 weeks prior
 to registration and/or randomization.

 12. Prior therapy with anti-vascular endothelial growth factor (VEGF) agents.

 13. Any of the following concurrent severe and/or uncontrolled medical conditions which
 could compromise participation in the study:

 -  Uncontrolled high blood pressure, history of labile hypertension, or history of
 poor compliance with an antihypertensive regimen

 -  Unstable angina pectoris

 -  Symptomatic congestive heart failure

 -  Myocardial infarction less than or equal to 6 months prior to registration and/or
 randomization

 -  Serious uncontrolled cardiac arrhythmia

 -  QTc interval > 450 milliseconds in males or > 470 milliseconds in females
 Uncontrolled diabetes

 -  Active or uncontrolled infection

 -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
 lung

 14. Acute or chronic liver disease (e.g. hepatitis, cirrhosis).

 15. Impairment of gastrointestinal (GI) function or GI disease that may significantly
 alter the absorption of PTK787/ZK 222584 (i.e., ulcerative disease, uncontrolled
 nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to
 swallow the tablets).

 16. Patients with confirmed diagnosis of human immunodeficiency virus (HIV) infection are
 excluded at the investigator's discretion if he/she feels that: a potential drug
 interaction between PTK787/ZK 222584 and any of the patient's anti-HIV medications
 could influence the efficacy of the anti-HIV medication, or it may place the patient
 at risk due to the pharmacologic activity of PTK787/ZK 222584.

 17. Patients who are taking therapeutic warfarin sodium (Coumadin) or similar oral
 anticoagulants that are metabolized by the cytochrome P450 system. Heparin is allowed.

 18. Patients unwilling to or unable to comply with the protocol.